English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
日本語
By Dean Seal
Shares of VistaGen Therapeutics surged in early trading after a Phase 3 study of company’s fasedienol nasal spray as a treatment for social anxiety disorder met its primary endpoint.
The stock reached a high of $24.71, up by a factor of 14 from last Friday’s close of $1.68, before retreating to $13.50 in early trading.
The San Francisco-based biopharmaceutical company said the study also met its secondary endpoint and was well-tolerated, with a favorable safety profile consistent with all prior trials.
VistaGen called its trial the first positive study of an investigational therapy for social anxiety disorder in over 15 years.
The rally comes just over a year after VistaGen’s PH94B nasal spray failed in a Phase 3 study by missing its primary endpoint in the treatment of adults with social anxiety disorder. The company said at the time that it would continue developing the spray.
Shares hit an all-time low of $1.62 at the end of June.
Write to Dean Seal at [email protected]
Read the full article here
